Key result
Screening identifies LRP6 as a BBB transcytosis receptor for engineered AAVs and IL3 for AAV9.
Why the study?
Lack of mechanistic insight into natural and engineered AAV vectors, especially those created by directed evolution, limits their application in gene delivery.
The identification of LRP6 as a blood-brain-barrier transcytosis receptor and IL3 as an AAV9 binder provides mechanistic insights that may inform the engineering of improved viral vectors for therapeutic delivery to the brain.
May inform AAV engineering for CNS delivery; hypothesis-generating from cell screening and requires in vivo human validation.
Adeno-associated viruses (AAVs) are foundational gene delivery tools for basic science and clinical therapeutics. However, lack of mechanistic insight, especially for engineered vectors created by directed evolution, can hamper their application. Here, we adapted an unbiased human cell microarray platform to determine the extracellular and cell surface interactomes of natural and engineered AAVs. We identified a naturally-evolved and serotype-specific interaction between the AAV9 capsid and human interleukin 3 (IL3), with possible roles in host immune modulation, as well as lab-evolved low-density-lipoprotein-receptor-related-protein 6 (LRP6) interactions specific to engineered capsids that cross the blood-brain barrier in non-human primates after intravenous administration. The unbiased cell microarray screening approach also allowed us to identify off-target tissue binding interactions of engineered brain-enriched AAV capsids that may inform vectors’ peripheral organ tropism and side effects. These results allow confident application of engineered AAVs in diverse organisms and unlock future target-informed engineering of improved viral and non-viral vectors for non-invasive therapeutic delivery to the brain.
No takes yet. Share an insight, caveat, or question.
Shay et al. (2024) studied this question. Engineered AAV capsids (AAV9-X1.1, CAP-Mac) vs. Natural AAV9 was evaluated on Identification of AAV binding partners. Unbiased human cell microarray screening identified LRP6 as a blood-brain-barrier transcytosis receptor for engineered AAVs and human IL3 as a specific binding partner for the AAV9 capsid.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: